Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tambiciclib added to venetoclax + azacitidine in newly diagnosed AML with inadequate response after 2 induction cycles
2025-524308-31-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of GFH009 in acute myeloid leukemia (AML) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Overall response rate at course 2. Planned start Oct 2026; status: authorised.
02
Drugs
GFH009
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-524308-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524308-31-00.